Andreas is a Scientific Officer at European Commission, DG Research and Innovation, Health Research, Unit Advanced technologies and systems medicine, in charge for immunization technologies and vaccines (disease cross-cutting) before this he worked for Unit Infectious Diseases, in charge for malaria research+ EDCTP. He holds a Postdoc at EstaciÃ³n Experimental del Zaidin, C.S.I.C, Granada, Spain: research on transcriptional regulation of environmentally stimulated bacterial promoters, PhD at AFRC Unit of Nitrogen Fixation/University of Sussex, Brighton, UK, Biological Sciences: thesis on “Regulation of nitrogen fixation genes in Enterobacteria, and a Diploma Thesis at University of Bayreuth, Dept. of Microbiology, Germany: on “Regulation of ammonium and methylammonium transport in bacteria.
Blogged on behalf of Milana Shapira and Sophia Doll
Dr Andreas Holtel from the European Commission spoke about vaccine R&D under the EU framework. Developing R&D in Europe is attractive from a policy point of view in many aspects, such as improving health, boosting industry and research, and fostering global cooperation. However, current frameworks under which vaccine policy falls, such as FP6 and FP7, are limiting. To tackle these, the new research and innovation framework program “Horizon 2020” is to be introduced, with hopes to tackle societal challenges, create industrial leadership and competitive frameworks, and support excellence in the science base, with a focus on developing infrastructure.
How do you feel vaccine R&D should fit under the EU framework? Tell us by commenting below!
The presentations from the event will be made available from the 1st November.
For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation